The grades of five pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

NuPathe Inc. (PATH) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.

This week, Mallinckrodt Plc (MNK) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). For more information, get Portfolio Grader’s complete analysis of MNK stock.

This week, Watson Pharmaceuticals’ (WPI) ratings are up from a B last week to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

This is a strong week for Impax Laboratories, Inc. (IPXL). The company’s rating climbs to B from the previous week’s C. Impax Laboratories develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. For more information, get Portfolio Grader’s complete analysis of IPXL stock.

Mylan (MYL) boosts its rating from a B to an A this week. Mylan is a global generic and specialty pharmaceuticals company. For more information, get Portfolio Grader’s complete analysis of MYL stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.